ROS-responsive bionanodrug for atherosclerosis therapy via regulating glycolipid metabolism and cell crosstalk.
A ROS-responsive nanosystem (TK-MLP@SR NPs) containing SKN and RSV is engineered, introducing a novel plaque environment-activated prodrug platform, providing valuable insights for clinical translation of AS therapy.